Insulin, Neurogenetics and Memory in Alzheimer's Disease
Phase 2
Completed
- Conditions
- Alzheimer Disease
- Registration Number
- NCT00018382
- Lead Sponsor
- US Department of Veterans Affairs
- Brief Summary
This study examines the use of insulin-sensitizing compounds, as therapeutic agents for cognitive impairment in Alzheimer's disease.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms link insulin resistance to cognitive decline in Alzheimer's disease?
How do insulin-sensitizing compounds compare to cholinesterase inhibitors in Alzheimer's treatment?
Which biomarkers correlate with response to insulin-sensitizing agents in Alzheimer's patients?
What adverse events are associated with intranasal insulin therapy in Alzheimer's trials?
Are there combination therapies involving insulin-sensitizers and amyloid-beta targeting drugs for Alzheimer's?
Trial Locations
- Locations (1)
VA Puget Sound Health Care System
🇺🇸Seattle, Washington, United States
VA Puget Sound Health Care System🇺🇸Seattle, Washington, United States